Matthew R Behrend1, Hao Hu2, Karima R Nigmatulina2, Philip Eckhoff2. 1. Intellectual Ventures Laboratory, 1555 132(nd) Ave. NE, Bellevue, WA 98005, USA. Electronic address: mbehrend@intven.com. 2. Intellectual Ventures Laboratory, 1555 132(nd) Ave. NE, Bellevue, WA 98005, USA.
Abstract
OBJECTIVE: To examine forces that drive vaccination policy to eradicate wild- and vaccine-derived poliovirus, and to focus on the efficacy of vaccines to support decision-making and further research. METHODS: We searched PubMed and Ovid databases for English-language publications, without date restrictions. We also collected references from major reviews on polio vaccine immunogenicity or protection. We conducted a meta-analysis of human immunity to polio infections using multiple non-linear regression, and built a database from a broad (but not systematic) set of polio vaccine studies (46 studies, >10000 subjects). RESULTS: The outcome was an immunological model representative of many different datasets. Parameters measured immunogenicity to both humoral and mucosal immune compartments for Salk and Sabin vaccines. The immunity model was more highly correlated with the data than a simpler per-dose efficacy model. CONCLUSIONS: The model offers new insights for immunization policy. We measured the mucosal immunogenicity of IPV to a precision that is useful in decision-making for end-game polio immunization policies.
OBJECTIVE: To examine forces that drive vaccination policy to eradicate wild- and vaccine-derived poliovirus, and to focus on the efficacy of vaccines to support decision-making and further research. METHODS: We searched PubMed and Ovid databases for English-language publications, without date restrictions. We also collected references from major reviews on polio vaccine immunogenicity or protection. We conducted a meta-analysis of human immunity to polio infections using multiple non-linear regression, and built a database from a broad (but not systematic) set of polio vaccine studies (46 studies, >10000 subjects). RESULTS: The outcome was an immunological model representative of many different datasets. Parameters measured immunogenicity to both humoral and mucosal immune compartments for Salk and Sabin vaccines. The immunity model was more highly correlated with the data than a simpler per-dose efficacy model. CONCLUSIONS: The model offers new insights for immunization policy. We measured the mucosal immunogenicity of IPV to a precision that is useful in decision-making for end-game polio immunization policies.
Authors: Michael Famulare; Stewart Chang; Jane Iber; Kun Zhao; Johnson A Adeniji; David Bukbuk; Marycelin Baba; Matthew Behrend; Cara C Burns; M Steven Oberste Journal: J Virol Date: 2015-10-14 Impact factor: 5.103
Authors: Alexander M Upfill-Brown; Hil M Lyons; Muhammad A Pate; Faisal Shuaib; Shahzad Baig; Hao Hu; Philip A Eckhoff; Guillaume Chabot-Couture Journal: BMC Med Date: 2014-06-04 Impact factor: 8.775
Authors: Bradley G Wagner; Matthew R Behrend; Daniel J Klein; Alexander M Upfill-Brown; Philip A Eckhoff; Hao Hu Journal: PLoS One Date: 2014-12-01 Impact factor: 3.240
Authors: Michael Famulare; Christian Selinger; Kevin A McCarthy; Philip A Eckhoff; Guillaume Chabot-Couture Journal: PLoS Biol Date: 2018-04-27 Impact factor: 8.029
Authors: Mami Taniuchi; Michael Famulare; Khalequ Zaman; Md Jashim Uddin; Alexander M Upfill-Brown; Tahmina Ahmed; Parimalendu Saha; Rashidul Haque; Ananda S Bandyopadhyay; John F Modlin; James A Platts-Mills; Eric R Houpt; Mohammed Yunus; William A Petri Journal: Lancet Infect Dis Date: 2017-07-07 Impact factor: 25.071
Authors: Rami Yaari; Ehud Kaliner; Itamar Grotto; Guy Katriel; Jacob Moran-Gilad; Danit Sofer; Ella Mendelson; Elizabeth Miller; Amit Huppert; E Anis; E Kopel; Y Manor; O Mor; L Shulman; R Singer; M Weil Journal: BMC Med Date: 2016-06-23 Impact factor: 8.775
Authors: Ananda S Bandyopadhyay; Edwin J Asturias; Miguel O'Ryan; M Steven Oberste; William Weldon; Ralf Clemens; Ricardo Rüttimann; John F Modlin; Chris Gast Journal: Vaccine Date: 2017-11-14 Impact factor: 3.641